Salsalate in Insulin-Resistant Patients: What Are The Benefits?
the MPR take:
In a new study, nondiabetic, insulin-resistant patient taking the NSAID salsalate saw improvement in fasting, but not postprandial, glucose and triglyceride concentrations. Forty-one adults were randomized to receive 3.5g of salsalate daily for four week or placebo; salsalate improved fasting (% mean change −7% [95% CI −10–−14] vs. 1% [−3–5], P=0.005), but not postprandial glucose concentration vs. placebo. Salsalate lowered fasting triglyceride concentration (−25% [−34–−15] vs. −6% [−26 to 14], P=0.04). Salsalate had no effect on SSPG concentration or insulin secretion rate yet did significantly decrease insulin clearance rate vs. placebo (−23% [−30–−16] vs. 3% [−10 –15], P< 0.001).
OBJECTIVE: Salsalate treatment has been shown to improve glucose homeostasis, but the mechanism remains unclear. The aim of this study was to evaluate the effect of salsalate treatment on insulin action, secretion, and clearance rate in nondiabetic individuals with insulin resistance. 1% [-3–5], P=0.005) but not postprandial glucose concentration compared with placebo.
READ FULL ARTICLE From Diabetesjournals